Skip to main content
OpenTrials
Completed

NCT Number: NCT06122467

A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms

This twelve-week trial will examine the effectiveness of a Menning Labs EQ Product Line acne product. Participants will use the exfoliating cleanser, cream, and gel daily for 8 weeks. Participants will complete questionnaires at Baseline, Day 1, Day 3, Day 7, Day 28, Day 42, and Day 56. Participants will also provide before-and-after photos at Baseline, Day 7, and Day 42, as well as undergo expert skin grading at Baseline and Day 42. The questionnaire on Day 56 will mark the conclusion of the trial.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acne Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Santa Monica, California, 90404, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be aged between 18-45.
  • Anyone who has acne prone skin and a history of recurring acne.
  • Has visible acne at enrollment.
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Have a digital camera or smartphone to take photos of the face.

Exclusion criteria

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone currently using a prescription skin product.
  • Anyone who is unwilling to stop using the current acne supplements they are taking.
  • Anyone with known severe allergic reactions.
  • Any women who are pregnant, breastfeeding or attempting to become pregnant.
  • Anyone unwilling to follow the study protocol.
  • Anyone who identifies as having sensitive skin.

Treatment and study plan

EQ Exfoliating Cleanser

Other

Product contains: Purified water, disodium laureth sulfosuccinate, coco betaine, decyl glucoside, Juglans regia (walnut) shells, PEG-40 hydrogenated castor oil, sodium cocoyl isethionate disodium cocoyl glutamate, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), Aloe barbadensis (aloe vera) leaf juice concentrate (Aloe barbadensis leaf juice, potassium sorbate, sodium benzoate, citric acid).

EQ Gel

Other

Product contains: Purified water, witch hazel (containing 14% grain alcohol), PEG-40 hydrogenated castor oil, ethoxydiglycol, xanthan gum, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), xanthan gum.

EQ Moisturizer

Other

Product contains: Purified water, glycerin, dicaprylyl carbonate, cetyl alcohol, glyceryl stearate citrate, squalane, PEG-40 hydrogenated castor oil, caprylic/capric triglycerides, stearic acid, jojoba oil, phenoxyethanol SA (phenoxyethanol, caprylyl glycol, sorbic acid), ethoxydiglycol, Root Blend Preservative (hexylene glycol, caprylyl glycol, Wasabia japonica (wasabi) root extract, Zingiber officinale (ginger) root extract, Allium sativum (garlic) bulb extract), allantoin, sodium carbomer.

Primary outcomes

  1. Change in the appearance of facial skin acne. [Timeframe: Baseline to Day 56]

    Time frame: 56 days

    Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.

    Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.

  2. Changes in skin clarity i.e. reduction in acne or associated blemishes. [Timeframe: Baseline to Day 56]

    Time frame: 56 days

    Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.

    Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.

Secondary outcomes

  1. Changes in overall skin health. [Timeframe: Baseline to Day 56]

    Time frame: 56 days

    Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.

    Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.

  2. Changes in skin texture. [Timeframe: Baseline to Day 56]

    Time frame: 56 days

    Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.

    Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.

  3. Changes in facial skin irritation. [Timeframe: Baseline to Day 56]

    Time frame: 56 days

    Surveys will be completed independently by study participants. Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").

  4. Changes in skin redness. [Timeframe: Baseline to Day 56]

    Time frame: 56 days

    Assessed via expert skin grading of baseline and endline photos conducted by a board-certified dermatologist.

    Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe"). Surveys will be completed independently by study participants.

  5. Changes in skin smoothness. [Timeframe: Baseline to Day 56]

    Time frame: 56 days

    Assessed by surveys completed independently by study participants. Study-specific surveys using a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").

Sponsors and collaborators

Lead sponsor

Menning Labs

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Nov 8, 2023
Registry last updated
Mar 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.